NCT05675072 - Evaluate the Efficacy and Safety of FB2001 for Inhalation in Patients With Mild to Moderate COVID-19 | Biotech Hunter

Enrollment

1,336

Participants

Timeline

Start Date

January 4, 2023

Primary Completion Date

September 30, 2023

Study Completion Date

December 31, 2023

Conditions

Mild to Moderate COVID-19

Interventions

DRUG

FB2001

FB2001 for Inhalation will be reconstituted with normal saline prior to nebulized inhalation. FB2001 will be administered by nebulized inhalation.

DRUG

FB2001 placebo

FB2001 placebo will be reconstituted with normal saline prior to nebulized inhalation. FB2001 placebo will be administered by nebulized inhalation.

Trial Locations (1)

RECRUITING

Shenzhen Third People's Hospital, Shenzhen